Hepsulfam

Drug Profile

Hepsulfam

Alternative Names: NSC 329680

Latest Information Update: 10 Dec 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Mayo Clinic
  • Class Antineoplastics; Small molecules
  • Mechanism of Action DNA inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 10 Dec 2007 Discontinued - Phase-I for Cancer in USA (unspecified route)
  • 27 Aug 1999 Sanofi and Synthélabo have merged to form Sanofi-Synthélabo
  • 27 Sep 1995 Data have been added to the therapeutic trials, pharmacokinetics and adverse events sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top